MariMed Inc: Among A Select Few U.S. Cannabis Operators Generating Free Cash Flow And Positive Net Income

In a world where many U.S. cannabis multi-state operators (MSOs) laud the their ability to generate positive Adjusted EBITDA, MariMed, Inc. (OTCMKTS: MRMD, CSE: MRMD) goes a couple of steps further. As their most recent financials show, MariMed is generating substantial free cash flow, allowing them to expand both their asset base and cash reserves while growing the core business at a measured clip.

The financials of reference are MariMed’s fiscal first quarter ended March 31, 2022. Despite incredibly difficult market conditions—exacerbated by widescale price compression predicted by Cantor Fitzgerald analyst Pablo Zuanic in Q3, 2021—the company delivered growth. According to the report, MariMed managed to increase sequential revenue by +0.77% while elevating gross margin by 437 basis points (54.26% in Q1 2022 from 49.89% in Q4 2021), despite most competitor MSOS experiencing margin contraction.

But perhaps the most indicative tell of MariMed’s operational success comes courtesy of its ability to maintain positive free cash flow in tough retail conditions.

Free cash flow (FCF) is one of the key benchmarks all companies must achieve in their quest for all-in profitability. It is defined as the cash that a company generates from its business operations after subtracting capital expenditures. Thus, free cash flow can be calculated using the balance sheet and cash flow statements in a company’s financial statement using the simple formula: Free cash flow = ​Operating cash flow (OCF)  − Capital expenditures (CAPEX).

While there are different ways to measure OCF to get to slightly different conclusions, we sourced the “Net cash provided by operating activities” from the cash flow statement (10-Q), which showed a $8,490,000 gain in fiscal Q1 2022. We then subtracted that total from CAPEX, defined as a net Increase in PP&E (Property, Plant, Equipment) + Depreciation expense, which gave us a total of $4,034,000.

After running the numbers, we estimate MariMed produced net free cash flow of approximately $4.46 million in Q1 2022, which was instrumental in allowing cash and cash equivalents to rise by $3.78 million sequentially over the previous quarter. This calculation matched the FCF calculations provided by Echelon Capital Markets, which estimated Adj. FCF of $4.4 million (green highlight) in Q1 2022.

Source: Echelon Capital Markets research coverage on MariMed, May 11, 2022

Furthermore, free cash flow yield registered by MariMed last reporting quarter were better than most Tier-1 MSOS that grab the majority of the headlines. At least last reporting quarter, MariMed’s produced by far the best FCF% of any of the majors, which matters because companies that generate more cash flow than they spend are less reliant on the capital markets for external financing. In these market conditions, that goes a long way.

Free Cash Flow Yield (%), Select Tier-1 MSOS

CompanyMost Recent QuarterFree Cash Flow Yield (%)
Ayr WellnessQ1 2022-15.06
Cresco LabsQ1 2022N/A
Curaleaf HoldingsQ1 2022-3.27
Green Thumb IndustriesQ1 2022-0.75
MariMed Inc.Q1 20227.5
TerrAscend Corp.Q1 2022-5.5
Trulieve CannabisQ1 2022-7.37
Verano HoldingsQ1 20221.4

If net income is your thing, MariMed is predictably on the black side of the ledger as well. They join Green Thumb Industries as the only Tier-1 MSOS that was net income positive last quarter from our sample list.

Revenue and Net Income/Loss, Select Tier-1 MSOS

CompanyMost Recent QuarterRevenue Net Income/Loss ($millions)
Ascend WellnessQ1 2022$85.09M(27.81)
Ayr WellnessQ1 2022$140.88M(9.60)
Cresco LabsQ1 2022$271.55M(34.68)
Curaleaf HoldingsQ1 2022$396.55M(19.98)
Green Thumb IndustriesQ1 2022$307.28M28.94
MariMed Inc.Q1 2022$31.28M4.19
TerrAscend Corp.Q1 2022$62.9M(20.72)
Trulieve CannabisQ1 2022$403.23M(32.48)
Verano HoldingsQ1 2022$256.15M(8.87)

Net income is generally defined as gross profit minus all other expenses and costs as well as any other income and revenue sources that are not included in gross income. These would include things such as interest on debt, taxes, and operating expenses or overhead costs. It is a useful number for investors to assess how much revenue exceeds the expenses of an organization.

Final Thoughts

From a cash flow generating perspective, MariMed is pound-for-pound one of the more impressive publicly traded multi-state operators on the exchanges. This past quarter, its retail operating model was put to the test and delivered another profitable quarter, while increasing gross margin percentage where competitors lagged. Trading at a valuation discount to many of its peers on an EBITDA basis, MariMed can be considered a good value play for investors looking for consistent results driven by operational and fiscal discipline.


* In accordance with an executed agreement between The Dales Report and MariMed, The Dales Report is engaged with the aforementioned on a 12-month contract for $7,500 per month, with the purpose of publicly disseminating information pertaining to MariMed via The Dales Report’s media assets, encompassing its website, diverse social media platforms, and YouTube channel. Compensation for The Dales Report services involves the receipt of a predefined monetary consideration, which may, on certain occasions, encompass ordinary shares in instances where monetary compensation was not obtained. In such instances where share compensation was received, The Dales Report hereby asserts the right to engage in the acquisition or disposition of such shares subsequent to the conclusion of the aforementioned contractual period, in compliance with provincial, state, and federal securities regulations. Please refer to the “Disclosures” section below, which is to be interpreted in conjunction with this disclaimer.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More